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In the treatment of rhesus hemolytic disease,
blood transfusion of babies still in utero has
become established for the removäl of life
' 'threatening anemia. In Hamburg-Eppendorf,
prenatal blood substitutions have been carried
out since 1966 and, so far, 252 transfusions in
130 fetuses have been successful. The success
rate amounts to 53%. If one excludes the
children who at the time of their first transfusion
already showed ascites and hence were treated
too late, then among 91 transfused children
56 (61.5%) survived. As prenatal transfusions
carry a risk, especially for the fetus, we should
attempt to answer the following questions:
1. Are prenatal transfusions warranted in
the presence of existing hydrops ?
2. At what amniotic fluid bilirubin values
are such prenatal procedures unsuccess-
ful?
3. Is the technical risk of prenatal trans-
fusion before the 27th week unacceptably
high?
Up to now, 39 babies, whose ascites was aspirated
at the time of their first transfusion, have received
äs many äs 4 transfusions (Fig. 1). The earliest
successful transfusion was in the 24th week.
13 children survived. The amount of ascites
ranged from l to 200 mls. It was rarely possible
to remove enough of the ascites to prevent
dilution of the transfused blood in the babies'
abdomen. According to our observations, the
amount of ascites aspirated at the first transfusion
correlates with the prognosis (Tab. I).
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baby is much larger when the amount of ascites
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Fig. 1. Babies with ascites at the first transfusion (n = 39).
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Tab. II. Severity of the rhesus hemolytic disease and
^E450 in the amniotic fluid.
^E450 0.4—0.499: 14 babies
(5 lived)
a) 6 Hydrops (all died)
b) 8 No hydrops (5 healthy, 3 dead)
^E450 0.5—0.599: 6 babies
(2 lived)
a) 4 Hydrops (l healthy, 3 dead)
b) 2 No hydrops (l healthy, l dead)
^E4,0 0.6 and higher: 12 babies
(l lived)
a) 11 Hydrop (l C. P., 10 dead)
b) No hydrops (l dead)
Basically, however, these results show that
prenatal treatment is warranted even in children
with already existing ascites.
We got the following results to the question at
which amniotic fluid bilirubin values prenatal
transfusions are unsuccessful (Tab. II).
Out of 32 babies in whom amniotic fluid bilirubin
values of 0.4 and higher were demonstrated, 21
showed a generalised hydrops at the time of
Tab. III. First prenatal transfusions before the 27th week
(36 babies).
living: 17 (47%) dead: 19 (53%)
(no hydrops) before the second pre-
natal transfusion:
9 (7 hydrops)
4 ascites at the time of the first transfusion 6
0.339 «0 0.474
(0.20—0.589) (0.21—1.83)
2 out of 36 babies probably died äs a result of the technical
Operation
birth. 8 children survived, 2 despite their hydrops.
19 of the dead children had hydrops at the time
of birth. The cause of death in the children not
affected by hydrops was, in most cases, extreme
prematurity. Although babies with bilirubin
levels from 0.4—0.6 still have a good change of
survival, the prospects, when the values are over
0.6, are very poor. SCHREINER and MARONI [7]
got corresponding results.
Tab. III shows the technical risk of prenatal
transfusions before the 27th week.
Out of 36 babies who were transfused for the
first time before the 27th week, 17 survived,
even though 4 of them already had a few mls of
ascites. Of the 19 dead babies, their deteriorating
condition was partly the cause of death and in
them the average amniotic fluid bilirubin values
was 0.474. Nine children died at the time of their
second transfusion, 2 of them not having hydrops.
In these two cases, death must be attributed to
the technical procedure. The risk, in our ex-
perience, therefore comprises about 6%.
Summary
Prenatal blood transfusion of a fetus established anemia
due to rhesus hemolytic disease can be life saving. In Ham-
burg-Eppendorf 252 transfusions in 130 babies have so far
been carried out. The success rate was 51%. Out of 39 ba-
bies who had ascites at the time of the first transfusion, 13
survived. The amount of ascites aspirated at the first trans-
fusion correlates with the prognosis: The chance of pro-
ducing a living and healthy child is greater when the amount
of ascites is under 5 mls than when it is over 5 mls. Babies
with amniotic fluid bilirubin values from 0.4 to 0.6 still have
a good chance of survival, whereas the prospects of success
with values over 0.6 are very small. The technical risk of pre-
natal transfusion before the 27th week amounts, according
to our observations, to about 6%.
Keywords: Amniotic fluid, bilirubin, hydrops fetalis, intra-uterine transfusion, rhesus hemolytic disease.
Zusammenfassung
Grenzen der pränatalen Therapie bei schwerer Rh-
Erythroblastose
Die pränatale Bluttransfusion kann bei einer ausgeprägten
fetalen Anämie infolge einer Rh-Erythroblastose lebens-
rettend sein. In Hamburg-Eppendorf erfolgten bisher 252
intrauterine Transfusionen bei 130 Kindern. Die
Erfolgsrate beträgt 51%. Bei 39 Kindern bestand 2. Zt.
der ersten Transfusion ein Ascites. 13 Kinder über-
lebten. Eine prognostische Aussage hat die Menge des bei
der ersten Transfusion aspirierten Ascites: Bei einer
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Ascitesmenge unter 5 ml ist die Chance zu lebenden und
gesunden Kindern zu kommen größer als bei Ascites-
mengen über 5 ml. Kinder mit Bilirubinwerten von
0,4—0,6 im Fruchtwasser haben noch gute Überlebens-
chancen, dagegen sind die Erfolgsaussichten bei Bilirubin-
werten über 0,6 sehr gering. Das technische Risiko der
praenatalen Transfusion vor der 27. Woche beträgt nach
den eigenen Beobachtungen etfwa 6%.
Schlüsselwörter: Fruchtwasser und Bilirubin, Hydrops fetalis, intrauterine Transfusion, Rhesus-Erythroblastose.
Resume
Limites de la therapie prenatale dans les cas d'ery-
throblastose Rh grave
La transfusion sanguine prdnatale peut sauver la vie en cas
d'anemie foetale aigüe, consequente ä une erythroblastose
Rh. A Hamburg-Eppendoff, on a effectue jusque lä 252
transfusions intrauterines a 130 enfants. Le taux de
succes est de 51%. 39 enfants avaient de Pascite au
moment de la premiere transfusion, 13 survecurent.
La quantite de l'ascite aspiree ä la premiere transfusion
possede une valeur prognostique: La chance de naissance
d'enfants vivants et sains est plus grande lorsque cette
quantito d'ascite est in&rieure ä 5 ml. Les enfants ayant des
valeurs de bilirubine de 0,4—0,6 däns le liquide amniotique
ont encore de bonnes chances de sürvie; par contre,
celles-ci sont tres reduites pour les valeurs de bilirubine
suporieures ä 0,6. Le risque technique de la transfusion
prenatale avant la 27eme semaine s'eleve, selon nos propres
observations, ä environ 6%.
Mots-cles: Erythroblastose Rhesus, hydrops fetalis, liquide amniotique et bilirubine, transfusion intrauterine.
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